Sutro Biopharma (STRO) EBT (2017 - 2025)

Sutro Biopharma has disclosed EBT across 9 years of filings, most recently posting -$46.8 million for Q4 2025.

• EBT for Q4 2025 came in at -$46.8 million, down 130.22% year-over-year; the trailing twelve-month figure through Dec 2025 was -$180.5 million (changed N/A YoY), and the FY2025 annual result was -$191.2 million, changed N/A from the prior year.
• EBT came in at -$46.8 million for Q4 2025 at Sutro Biopharma, up from -$56.9 million in the prior quarter.
• In the past five years, EBT ranged from a high of $155.0 million in Q4 2024 to a low of -$65.3 million in Q1 2025.
• The 5-year median for EBT is -$38.2 million (2021), against an average of -$24.0 million.
• Across the five-year window, EBT slumped 282.18% in 2022 and surged 235.49% in 2023, its largest moves.
• Sutro Biopharma's EBT stood at -$38.1 million in 2021, then gained by 9.26% to -$34.6 million in 2022, then soared by 235.49% to $46.9 million in 2023, then surged by 230.71% to $155.0 million in 2024, then plunged by 130.22% to -$46.8 million in 2025.
• The last three EBT figures came in at -$46.8 million (Q4 2025), -$56.9 million (Q3 2025), and -$11.5 million (Q2 2025), per Business Quant data.